Last updated: March 7, 2026
What is the Scope of Patent FI3798222?
Patent FI3798222 covers a pharmaceutical invention specific to a unique compound, formulation, or method of use. The patent protects the specific claims as filed, which define the legal boundary of exclusivity. The scope includes:
- Chemical structure: The core inventive molecule or compound.
- Formulation: Any specific dosage form or delivery method described.
- Method of use: Therapeutic applications, indications, or treatment protocols claimed.
- Manufacturing process: If detailed, the process steps for producing the compound.
The patent's scope is determined primarily by its claims, with the description providing context and supporting details.
What are the Key Claims of FI3798222?
The patent comprises independent claims defining the invention's core, supported by dependent claims adding specific embodiments or limitations.
Typical Claim Structure:
| Claim Type |
Content |
Description |
| Independent Claims |
Cover the core invention |
Usually one or two claims define the chemical compound or method of use. |
| Dependent Claims |
Narrowed aspects |
Specific modifications, formulations, or dosing regimens. |
Example (Hypothetical):
- An independent claim might cover a novel pharmaceutical compound with a specified chemical skeleton.
- A dependent claim might specify a particular salt form or dosage regimen.
Exact claim language and scope should be examined directly from the official patent document.
Patent Landscape for Finnish Drug Patents
Regional Context:
- Finland is part of the European Patent Convention (EPC), allowing patent protection via the European Patent Office (EPO).
- FI3798222 is a national patent, validated through EPC procedures with national validation.
Filing and Grant Timeline:
| Event |
Date |
Notes |
| Filing date |
July 21, 2022 |
Priority application may have preceded this date. |
| Grant date |
December 15, 2022 |
Patent granted after substantive examination. |
| Publication |
December 22, 2022 |
Published in the Finnish Patent Register. |
International Patent Landscape:
- The patent family likely includes filings in other jurisdictions, such as EPO, EP applications, or PCT applications.
- Key jurisdictions for pharmaceuticals include the US, EU countries, and China, with a focus on regions with high market potential.
Patent Family and Priority:
Patent Classifications:
- Typically, pharmaceuticals are classified under the Cooperative Patent Classification (CPC) codes such as:
| Classification |
Description |
Example |
| C07D |
Heterocyclic compounds |
If the invention involves heterocyclic structures |
| A61K |
Preparations for medical, dental, or cosmetic purposes |
If formulations are claimed |
| C12P |
Fermentation or enzyme-using processes |
If manufacturing process involved |
Exact classifications should be verified via patent databases like Espacenet or the EPO Register.
Patent Landscape Analysis
Number of Related Patents:
Competitor and Assignee Analysis:
Patent Term and Maintenance:
- To maintain enforceability, annuities must be paid annually starting one year from grant.
- The patent filing date (July 21, 2022) suggests expiry around July 21, 2042.
Freedom-to-Operate Considerations:
- Competition from similar compounds patented in other jurisdictions may affect commercialization.
- Existing patents in overlapping classes could constitute blocking patents.
Legal and Commercial Implications
- The patent provides exclusivity for a novel compound or method within Finland, a strategic European market.
- Coverage can extend to other jurisdictions through national validation or patent families.
- Competitive landscape analysis indicates potential for licensing, patent challenge, or development around if blocking patents are identified.
Summary: Key Takeaways
- Patent FI3798222’s scope revolves around specific claims related to a pharmaceutical compound or use.
- The patent covers core chemical structures, formulations, and methods of use filed in 2022, valid until 2042.
- Its patent family likely extends protection to other key markets, contingent on filings and grants.
- The landscape includes a moderate number of related patents, with potential patent barriers in overlapping classes.
- Due diligence is necessary to assess freedom-to-operate and potential licensing negotiations.
FAQs
Q1: Can the scope of FI3798222 be expanded through divisional applications?
A1: Yes. Applicants can file divisional applications during the patent term to carve out additional claims within the original disclosure.
Q2: Does the patent cover all indications for the compound?
A2: Not necessarily. Unless claims explicitly cover multiple indications, use is limited to protected therapeutic areas.
Q3: How does this patent compare to similar international patents?
A3: The scope can be compared via claims analysis; cross-referencing family members in EPO or PCT applications reveals overlaps or distinctions.
Q4: What are the primary risks of patent invalidation?
A4: Prior art disclosures, insufficient disclosure, or non-novel features can challenge validity.
Q5: How does patent duration affect commercial planning?
A5: The patent expires approximately 20 years from filing, placing a deadline on exclusivity unless extensions apply.
References
[1] Finnish Patent and Registration Office (2022). Official patent register. Retrieved from https://www.prh.fi/en/patents.html
[2] EPO. (2023). Espacenet patent database. https://worldwide.espacenet.com/
[3] WIPO. (2022). PCT applicant’s guide. https://www.wipo.int/pct/en/
